Inflammatory Bowel Disease (IBD) is a group of chronic inflammatory conditions affecting the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis.
Ranked by community outcomes, then evidence grade, Health Voice mentions, and recency.
Why it may help Inflammatory Bowel Disease: Improves IBD outcomes
Why it may help Inflammatory Bowel Disease: Repairs gut lining
Why it may help Inflammatory Bowel Disease: A Low-FODMAP Diet reduces fermentable carbohydrates that can exacerbate gut symptoms by decreasing osmotic load and gas production, thereby alleviating abdominal pain and bloating in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Reduces UC severity
Why it may help Inflammatory Bowel Disease: DGL Licorice may help Inflammatory Bowel Disease by promoting mucus secretion and inhibiting inflammatory mediators, which can protect the gastrointestinal lining and reduce inflammation.
Why it may help Inflammatory Bowel Disease: L-Glutamine supports the integrity of the intestinal barrier by providing fuel for enterocytes and strengthening tight junctions, which can reduce gut permeability and inflammation in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Bovine Colostrum contains immunoglobulins and growth factors that can modulate the immune response and promote gut barrier repair, potentially reducing inflammation and improving symptoms in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Butyrate (Tributyrin) serves as a primary energy source for colonocytes, promoting gut barrier integrity and reducing inflammation in the colon, which can alleviate symptoms of inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Zinc Carnosine stabilizes the intestinal barrier by strengthening tight junctions and reducing inflammation, thereby helping to alleviate symptoms and promote healing in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Often deficient in IBD
Why it may help Inflammatory Bowel Disease: Marshmallow Root contains mucilage that coats and soothes the inflamed gastrointestinal lining, reducing irritation and supporting mucosal integrity in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Krill oil, rich in EPA and DHA, reduces inflammation by modulating immune responses and prostaglandin synthesis, which can alleviate intestinal inflammation in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Slippery Elm forms a protective mucilaginous layer on the inflamed intestinal lining, reducing irritation and promoting healing in individuals with inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Curcumin maintains UC remission
Why it may help Inflammatory Bowel Disease: VSL#3 strain helps ulcerative colitis
Inner-leaf aloe juice traditionally used for digestion, gut healing, and as a soothing tonic; also reported to support thyroid health.
Why it may help Inflammatory Bowel Disease: Algal oil, a source of anti-inflammatory omega-3 fatty acids EPA and DHA, can reduce gut inflammation by modulating immune pathways, thereby alleviating symptoms of inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Flaxseed oil, rich in alpha-linolenic acid (ALA), can reduce inflammation by modulating immune responses and prostaglandin synthesis, potentially alleviating intestinal inflammation in inflammatory bowel disease.
Why it may help Inflammatory Bowel Disease: Omega-3 fatty acids, particularly EPA and DHA, reduce inflammation by modulating immune responses and decreasing pro-inflammatory cytokine production, which can alleviate intestinal inflammation in inflammatory bowel disease.
Community outcomes
Self-reported by community members · not medical advice.
Self-reported community outcomes. Not medical advice. Requires at least three reports per remedy to surface.
Community outcome data is still being collected for this ailment.
Be the first to share your experience →As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Structured experience reports from people managing this condition. Not medical advice.
You can share without an account — we'll send a one-time code to verify your email. Or sign in.
Loading posts…
Community Discussions
How global health authorities view Inflammatory Bowel Disease.
Major health bodies generally emphasize conventional medical therapies for IBD, including anti-inflammatory drugs, immunosuppressants, and biologics. While they acknowledge the role of diet and lifestyle, specific natural remedies are often viewed as complementary rather than primary treatments. The NCCIH notes that some complementary approaches, like probiotics, may have a role in specific IBD contexts, but often highlight the need for more rigorous research. The Mayo Clinic suggests that some dietary changes and stress reduction may help manage symptoms, but advises against relying solely on alternative therapies. Cochrane reviews have explored various complementary therapies, with some showing limited or inconclusive evidence for efficacy in IBD.
Indexed studies for Inflammatory Bowel Disease, grouped by source type and quality.
Filter by source type
Pooled analyses across multiple human trials.
Yang H, An T, Zhao Y, Shi X, Wang B, Zhang Q · Annals of medicine · 2025
Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients. Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions. A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (
Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP · Inflammatory bowel diseases · 2024 · n=454
Inflammatory bowel disease (IBD) is a multisystem disease impacting various body systems including musculoskeletal, ocular, skin, hepatobiliary, pulmonary, cardiac, and haematological systems. The extraintestinal manifestations of IBD are frequent, common in both ulcerative colitis (UC) and Crohn's disease (CD), and impact the morbidity and mortality of patients. The Embase, Embase classic, and PubMed databases were searched between January 1979 and December 2021. A random effects model was performed to find the pooled prevalence of joint, ocular, and skin extraintestinal manifestations of UC and CD. Fifty-two studies were included that reported on 352 454 patients. The prevalence of at least 1 joint, ocular, or skin extraintestinal manifestation in all IBD, UC, and CD was 24%, 27%, and 35% respectively. The prevalence between UC and CD were similar for pyoderma gangrenosum and axial joint manifestations. Ocular manifestations were found to be more common in CD than in UC. Per
Chatterjee A, Kaur S, Jena A, Patil AN, Dutta U, Sebastian S · Journal of gastrointestinal and liver diseases : JGLD · 2024 · n=960
Colonoscopy has a vital role in the diagnosis of inflammatory bowel disease (IBD), as well as in the estimation of disease severity, monitoring response to therapy, and surveillance for neoplasia. We performed a systematic review of randomised trials of various bowel preparations for colonoscopy in IBD. We searched various electronic databases (PubMed, Embase, and CENTRAL) for studies reporting about the use of various strategies to improve colonoscopy preparation in IBD. We included only randomized clinical trials (RCTs). A network meta-analysis was done using a frequentist approach to compare the effectiveness of various bowel preparations. The risk of bias was assessed using Cochrane risk of bias tool 2.0. Other outcome parameters like compliance, tolerance, acceptance, and adverse effects were assessed qualitatively. Seven RCTs reporting about 960 patients were included. On comparison with 4 liter (L) of poliethylen glycol (PEG), oral sulfate solution (OR=1.1, 95%CI: 0.65-1.86);
Structured reviews of the full body of evidence (incl. Cochrane).
Valvano M, Capannolo A, Cesaro N, Stefanelli G, Fabiani S, Frassino S · Nutrients · 2023
During the disease course, most Inflammatory Bowel Disease patients present a condition of malnutrition, undernutrition, or even overnutrition. These conditions are mainly due to suboptimal nutritional intake, alterations in nutrient requirements and metabolism, malabsorption, and excessive gastrointestinal losses. A suboptimal nutritional status and low micronutrient serum levels can have a negative impact on both induction and maintenance of remission and on the quality of life of Inflammatory Bowel Disease patients. We performed a systematic review including all the studies evaluating the connection between nutrition, nutrition status (including undernutrition and overnutrition), micronutrient deficiency, and both disease course and therapeutic response in Inflammatory Bowel Disease patients. This systematic review was performed using PubMed/MEDLINE and Scopus. Four main clinical settings concerning the effect of nutrition on disease course in adult Inflammatory Bowel Disease patien
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Sniffen JC, McFarland LV, Evans CT, Goldstein EJC · PloS one · 2018
Clinicians and patients face a daunting task when choosing the most appropriate probiotic for their specific needs. Available preparations encompass a diverse and continuously expanding product base, with most available products lacking evidence-based trials that support their use. Even when evidence exists, not all probiotic products are equally effective for all disease prevention or treatment indications. At this point in time, drug regulatory agencies offer limited assistance with regard to guidance and oversight in most countries, including the U.S. We reviewed the current medical literature and sources on the internet to survey the types of available probiotic products and to determine which probiotics had evidence-based efficacy data. Standard medical databases from inception to June 2018 were searched and discussions with experts in the field were conducted. We graded the strength of the evidence for probiotics having multiple, randomized controlled trials and developed a guid
Recommendations from medical societies (NICE, AHA, ADA, ACG, Endocrine Society…).
Assa A, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M · Journal of pediatric gastroenterology and nutrition · 2025
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non-PICO based questions. Grading methodology was based on the Oxford Centre for Evidence-Based Medicine-Levels of evidence. The questions were addressed by working subg
Kucharzik T, Taylor S, Allocca M, Burisch J, Ellul P, Iacucci M · Journal of Crohn's & colitis · 2025
The current consensus guideline offers a comprehensive and practical guidance on the diagnostic and monitoring of patients with inflammatory bowel disease (IBD). It provides recommendations on requirements for initial diagnosis, detection of complications, the use of monitoring tools in patients with IBD and diagnostics in specific situations, such as pregnancy, postoperatively and for cancer surveillance. The guideline is a joint project of the European Crohn's and Colitis Organization (ECCO), the European Society of Gastrointestinal and Abdominal Radiology, the European Society of Pathology, and the International Bowel Ultrasonography Group under the leadership of ECCO.
Wine E, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M · Journal of pediatric gastroenterology and nutrition · 2025
Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face-to-face meeting. Thirty-nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Robust evidence-based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more 'tr
Controlled human studies with random assignment.
Wellens J, Vanderstappen J, Hoekx S, Vissers E, Luppens M, Van Elst L · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
Dietary emulsifier consumption might promote intestinal inflammation, eventually leading to inflammatory bowel diseases. However, human data are scarce and involve a limited number of emulsifiers. We studied the effects of an emulsifier-free diet (EFD) and specific emulsifier supplementation. Sixty healthy participants followed an EFD for 2 weeks. Then, using a randomized placebo-controlled trial design, participants continued an EFD for 4 weeks with the addition of either carboxymethyl cellulose, polysorbate-80, carrageenan, soy lecithin, native rice starch, or no additives administered through brownies. Effects on cardiometabolic markers, gut microbiota, intestinal inflammation, and permeability were explored. After 2 weeks of an EFD, cholesterol levels decreased (P = .00006). Under emulsifier supplementation, alpha diversity remained stable, yet microbial composition was affected by treatment and visit. Compared with placebo, concentrations of all short chain fatty acids were lowe
Erol Doğan Ö, Karaca Çelik KE, Baş M, Alan EH, Çağın YF · Nutrients · 2024
This study aimed to investigate the effects of the Mediterranean diet (MD), combined with curcumin and resveratrol supplementation, on disease activity, serum inflammatory markers, and quality of life in patients with mild-to-moderate active ulcerative colitis (UC). This study was designed as a prospective multicenter three-arm randomized controlled trial. Participants were randomized to the MD, MD + curcumin, and MD + resveratrol groups. All participants were placed on the MD for 8 weeks. The MD + curcumin group also received 1600 mg/day of curcumin supplementation, whereas the MD + resveratrol group received 500 mg/day of resveratrol supplementation for 8 weeks. Anthropometric measurements, Truelove-Witts Index, Short Form-36, Inflammatory Bowel Disease Questionnaire, Mediterranean Diet Adherence Scale (MEDAS), and laboratory tests were performed at baseline and postintervention. Within-group comparisons showed that MD, MD + curcumin, and MD + resveratrol interventions were effective
Wauters L, Slaets H, De Paepe K, Ceulemans M, Wetzels S, Geboers K · The lancet. Gastroenterology & hepatology · 2021 · n=68
Current treatments for functional dyspepsia have limited efficacy or present safety issues. We aimed to assess spore-forming probiotics in functional dyspepsia as monotherapy or add-on therapy to long-term treatment with proton-pump inhibitors. In this single-centre, randomised, double-blind, placebo-controlled pilot trial that took place at University Hospitals Leuven (Leuven, Belgium), adult patients (≥18 years) with functional dyspepsia (as defined by Rome IV criteria, on proton-pump inhibitors or off proton-pump inhibitors) were randomly assigned (1:1) via computer-generated blocked lists, stratified by proton-pump inhibitor status, to receive 8 weeks of treatment with probiotics (Bacillus coagulans MY01 and Bacillus subtilis MY02, 2·5 × 109 colony-forming units per capsule) or placebo consumed twice per day, followed by an open-label extension phase of 8 weeks. Individuals with a history of abdominal surgery, diabetes, coeliac or inflammatory bowel
Cohort, case-control, and cross-sectional human studies.
Diet and Microbiome-Directed Therapy 2.0 for IBD.
Ananthakrishnan AN, Whelan K, Allegretti JR, Sokol H · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that influence the onset and progression of IBD and can be leveraged for treatment. In this review, we summarize the current evidence on the role of the gut microbiome and diet in IBD pathogenesis, and the potential of microbiome-directed therapies and dietary interventions to improve IBD outcomes. We discuss available data and the advantages and drawbacks of the different approaches to manipulate the gut microbiome, such as fecal microbiota transplantation, next-generation and conventional probiotics, and postbiotics. We also review the use of diet as a therapeutic tool in IBD, including the effects in induction and maintenance, special diets, and exclusive enteral nutrition. Finally, we highlight the challenges and opportunities for the translation of di
McNeil R, Fredman D, Eldar O, Gafter-Gvili A, Avni T · Acta haematologica · 2024
Inflammatory bowel disease (IBD) patients are three times more likely to develop venous thromboembolism (VTE), and guidelines recommend prophylaxis during all hospitalizations. In this systematic review, we sought to assess for the benefits and risks of VTE prophylaxis in hospitalized IBD patients. We performed a systematic review and meta-analysis. We searched MEDLINE and others up to 2/2022, for studies on IBD inpatients treated with prophylactic anticoagulation during hospitalization, compared to no prophylaxis. Primary efficacy and safety outcomes were any VTE and major bleeding, respectively. Results were pooled using random-effects models, calculating odds ratios (OR), and 95% confidence intervals (CI). The ROBINS-I tool was used to assess bias. We extracted data from 18 observational studies and 2 randomized-trial subgroups. The studies were highly variable regarding the included populations, interventions, and outcome definitions. Meta-analysis of all studies showed a nonsign
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
Sudhakar P, Wellens J, Verstockt B, Ferrante M, Sabino J, Vermeire S · Gut · 2023
Inflammatory bowel disease (IBD) is an emerging global disease characterised by chronic inflammation of the gastrointestinal tract. However, IBD is also manifested by several extraintestinal symptoms which, along with the intestinal symptoms, impact on the mental and emotional well-being of patients. Despite therapeutic advancements, only one-third of the diagnosed patients receiving approved medical treatments achieve short-term to medium-term remission. Consequently, patients who do not get successfully treated might resort to using complementary and alternative approaches to manage their symptoms, with or without consulting their treating clinician. Despite their possible potential, such approaches have various risks stemming from unknown adverse reactions and possible interference with medically approved therapies. In this study, we present the results of a well-performed literature review where we included randomised clinical trials which have assessed the efficacy of complementar
Public-health agencies: NCCIH, NIH, CDC, NHS.
Inflammatory bowel disease (IBD)
NHS
The NHS provides an overview of inflammatory bowel disease, explaining the differences between Crohn's disease and ulcerative colitis. It offers insights into symptoms, diagnosis, and management from a UK healthcare perspective.
NHS
The NHS explains ulcerative colitis, including its symptoms, how it's diagnosed, and the various treatments available. It offers practical advice and information for those affected by the condition.
Registered ongoing or completed trials (ClinicalTrials.gov).
n=204 · NCT06867094 · RECRUITING · RECRUITING
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study). * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
n=360 · NCT07650942 · NOT_YET_RECRUITING · NOT_YET_RECRUITING
The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.
n=78 · NCT05138770 · COMPLETED · COMPLETED
This clinical trial consists of two parts：1. a randomized, double-blind, single-center, placebo-controlled, dose-escalation PK study; 2. food effects and drug metabolism transformation study. The main purpose of this trial is to evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Food effects of VC005 Tablets in healthy subjects.
Curated cross-source summaries (TRIP Database and similar).
Cochrane Library: Inflammatory Bowel Disease
Cochrane
The Cochrane Library provides systematic reviews and meta-analyses on various interventions for Inflammatory Bowel Disease. It offers high-quality evidence to inform clinical decision-making.
TRIP Database: Inflammatory Bowel Disease
TRIP Database
The TRIP Database is a clinical search engine designed to allow users to quickly and easily find high-quality research evidence to support their practice. Searching for 'Inflammatory Bowel Disease' provides access to a wide range of evidence-based resources.
Conventional treatment for IBD typically involves medications to reduce inflammation, such as aminosalicylates, corticosteroids, immunomodulators, and biologics. Surgery may be necessary in some cases to remove damaged portions of the intestine or to address complications. Regular monitoring by a gastroenterologist is crucial for managing the disease and preventing complications.
Latest News
Health Videos
This information is for educational purposes only and should not replace professional medical advice. Individuals with IBD should consult with their healthcare provider before making any changes to their treatment plan, diet, or supplement regimen.
Found something that helped your inflammatory bowel disease?
Help others see what actually works.
Found something that helped your inflammatory bowel disease?
Real-world results help others choose what's worth trying.